TelyRx Holdings Inc. is seeing a significant drop in stock value, which has raised concerns among investors.
Today, TelyRx Holdings Inc. (TELY.TO) is having a tough trading session, with shares falling by 5.77%. This decline is prompting investors to rethink their positions in the company, especially considering its recent performance and the current market conditions.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeAdvertisement
Market cap
$69.10M
52W high
$4.25
52W low
$2.00
1W change
+2.08%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 144.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+144.9% Upside
Current Price
C$2.45
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
111.2%
Annualized
90-Day Vol
101.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.05
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.31 | C$1.57 – C$3.39 |
| 60 trading days | C$2.18 | C$1.26 – C$3.74 |
| 90 trading days | C$2.05 | C$1.05 – C$3.98 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on TelyRx's financial health and market trends as the stock experiences volatility.
Stock Down 5.77% Today
TelyRx Holdings Inc. has a market cap of about CA$69 million, indicating its relatively small size in the competitive healthcare sector.
Bull case
Even with today’s drop, TelyRx has reported promising revenue growth, hitting $42.9 million for the year ending December 31, 2025. This could suggest potential for recovery in the future.
Bear case
The sharp decline in stock price today may point to underlying worries about the company’s profitability and market position, especially since it has a negative profit margin of -19.36%.
Advertisement
Market Performance Overview
TelyRx Holdings Inc. has seen its stock price decrease by 5.77% in today’s trading session, closing at CA$2.45. This drop has caught the attention of investors, particularly in light of the company’s recent financial announcements, including a notable revenue increase reported for the year ending December 31, 2025.
Financial Health and Future Outlook
Despite the current downturn, TelyRx's reported revenue growth could indicate potential for recovery. However, the company’s negative profit margin of -19.36% raises concerns about its long-term sustainability in the competitive healthcare market. Investors should stay alert for upcoming financial results and market trends that could affect TelyRx's performance. For more details, visit the TelyRx stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
